Benevolent Platform Precision Medicine
BAI-5028 is approaching Candidate seeking
2019
2020
2021
2022
2023
Q4
Q1
Q2
Q3 Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3 Q4
Target
validation
Preparation/Hit ID / Hit
expansion
Lead Optimisation
Advanced Lead
selection
Candidate profiling
Candidate
nomination
Preclinical
Key programme points:
Therapeutic target for GBM which functions as a radiosensitiser
identified using Benevolent Knowledge Graph-based relational
inference models
An attractive tech-derived virtual screening hit led to a potent,
selective, and highly brain-penetrant series of "Target R" kinase
inhibitors
"Target R❞ sensitive GBM patient cohort identified
using our Precision Medicine workflows for patient
stratification
Program on track to deliver within company timelines
Benevolent 57
ΑΙView entire presentation